Current Research Studies

SC-N188 Views and Outcomes with Immune effector Cell therapy (VOICE)

SC-N188 VOICE

  • Condition(s): Anus, Bones and Joints, Brain and Nervous System, Breast, Cervix, Colon, Corpus Uteri, Esophagus, Eye and Orbit, Hodgkin's Lymphoma, Ill-Defined Sites, Kaposi's Sarcoma, Kidney, Larynx, Leukemia, other, Lip, Oral Cavity and Pharynx, Liver, Lung, Lymphoid Leukemia, Melanoma, Skin, Multiple Myeloma, Mycosis Fungoides, Myeloid and Monocytic Leukemia, Non-Hodgkin's Lymphoma, Non-malignant Disease, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Hematopoietic, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid, Unknown Sites, Urinary Bladder
  • Phase: N/A
  • Clinicaltrials.gov ID: NA

What is the goal of the study?

This is a longitudinal study of patient-reported outcomes of children, adolescents, and young adults receiving immune effector cell (e.g., CAR-T) therapy at Seattle Children's Hospital. Participants will be asked to complete surveys at 7 longitudinal timepoints around immune effector cell therapy related to physical symptoms and psychosocial functioning. Data from this study will provide us with patient and caregiver perspectives of experiences with this novel therapy. Findings may help inform how we counsel patients receiving immune effector cell therapy in the future and also lead to innovative clinician-facing symptom monitoring interventions.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team: